HC Wainwright keeps Buy rating on Connect Biopharma with $7 price target
HC Wainwright reiterated its Buy rating on Connect Biopharma with a $7 target, citing rademikibart data from the Seabreeze study in COPD.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
HC Wainwright & Co. reiterated its Buy rating on Connect Biopharma Holdings and kept its $7.00 price target. According to TradingView, citing Benzinga data, the target implies an upside of 730.9% from the October 27 close of $0.84.
The analyst note highlights that rademikibart cut treatment failure by 81% in the Seabreeze study, well above what key opinion leaders consider clinically meaningful in COPD care. It also stresses that the drug acts during the initial exacerbation instead of waiting for stabilization, which sets it apart from existing treatments.
why it matters
A reiterated rating is a routine item and does not reflect a new company decision or earnings. For investors following the stock, the clinical data matters more, while the target sits far above a share price below one dollar.
tags
instruments
sources
- HC Wainwright & Co. reiterates Buy rating on Connect Biopharma Hldgs, $7 price target — TradingView, 28 October 2026 at 11:39 UTC
- HC Wainwright & Co. reiterates Buy rating on Neurogene, $65 price target — TradingView, 28 October 2026 at 11:37 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗